Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 2/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167002 | 1.00 | MAPK1 (0.45) | MAPK1DYRK1ACCR1CCR5CCR8 | |
| SCHEMBL1473269 | 0.74 | DYRK1A (0.53) | MAPK1DYRK1ACCR8AURKAPRKCI | |
| SCHEMBL21938395 | 0.74 | MAPK1 (0.45) | MAPK1DYRK1AIRAK4PRKCIAXL | |
| SCHEMBL27813658 | 0.74 | PRKCI (0.48) | MAPK1DYRK1APRKCIAXL | |
| SCHEMBL29691438 | 0.74 | DYRK1A (0.53) | MAPK1DYRK1ACCR8AURKAPRKCI | |
| SCHEMBL24348992 | 0.74 | MAPK1 (0.45) | MAPK1DYRK1APRKCIAXL | |
| SCHEMBL2628882 | 0.74 | MAPK1 (0.45) | MAPK1DYRK1AAURKAPRKCIAXL | |
| SCHEMBL20712736 | 0.74 | MAPK1 (0.41) | MAPK1DYRK1AIRAK4 | |
| SCHEMBL13524887 | 0.74 | MAPK1 (0.41) | MAPK1DYRK1AIRAK4TAAR1 | |
| SCHEMBL845394 | 0.74 | MAPK1 (0.41) | MAPK1DYRK1ANOS2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2024-08-22 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023125803-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-115768761-A | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2023-03-07 | — | — | CN | disclosed |
| EP-4129406-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | Carna Biosciences, Inc. (JP) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2021147974-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| CN-1404392-A | Antiviral azaindole derivatives | BRISTOL MYERS SQUIBB CO (US) | 2003-03-19 | — | — | CN | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | MAPK1 4078/4885DYRK1A 3956/4885CCR1 1543/4885 |
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | MAPK1 4078/4885DYRK1A 3956/4885CCR1 1543/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | MAPK1 4477/4885DYRK1A 4700/4885CCR1 223/4885 |
| US-20240279205-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE | STING1, IRF3, TBK1 | MAPK1 110/4885DYRK1A 3806/4885CCR1 2030/4885 |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | MAPK1 1509/4885DYRK1A 3525/4885CCR1 284/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | MAPK1 38/4885DYRK1A 618/4885CCR1 1697/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | MAPK1 648/4885DYRK1A 1896/4885CCR1 125/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | MAPK1 4078/4885DYRK1A 3956/4885CCR1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.